Tavokinogene telseplasmid is under clinical development by OncoSec Medical and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Tavokinogene telseplasmid’s likelihood of approval (LoA) and phase transition for Metastatic Melanoma took place on 16 Feb 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Tavokinogene telseplasmid Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Tavokinogene telseplasmid overview
Tavokinogene telseplasmid (DNA IL-12, Interleukin-12) is under development for the treatment of metastatic melanoma and solid tumor. The drug candidate is administered through intratumoral route. The drug candidate is being developed OMS electroImmunotherapy technology that allows delivery of a DNA (nucleic acid) based cytokine coded for interleukin-12, or DNA IL-12. The therapeutic candidate targets cell-surface receptor interleukin-12. It was also under development for the treatment of solid tumors, squamous merkel cell carcinoma, mycosis fungoides, metastatic cerival cancer, cutaneous T-cell lymphoma, head and neck cancer squamous cell carcinoma and triple negative breast cancer.
OncoSec Medical overview
OncoSec Medical (OncoSec) is a biotechnology company. The company offers services to stimulate body’s immune system and attack cancer. Its lead candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. OncoSec is conducting pipeline programs for various indications which include metastatic melanoma, triple negative breast cancer and solid tumors. The company is also identifying and developing novel immune-targeting agents for use with the immunogenicity platform. It conducts pre-clinical and clinical studies targeting various cancers in collaboration with various academic medical centers and companies. OncoSec is headquartered in San Diego, California, the US
Quick View Tavokinogene telseplasmid LOA Data
|Highest Development Stage|